Analyst Ratings For NASDAQ:KIN – Kindred Biosciences (NASDAQ:KIN)
Today, HC Wainwright raised its price target on NASDAQ:KIN – Kindred Biosciences (NASDAQ:KIN) to per share.
Some recent analyst ratings include
- 12/27/2017-CL King initiated coverage with a Neutral ➝ Neutral rating.
- 12/22/2017-BMO Capital Markets Reiterated Rating of Hold.
- 12/15/2017-Aegis Reiterated Rating of Buy.
- 5/31/2017-FBR & Co Reiterated Rating of Buy.
- 1/3/2017-Feltl & Co. Reiterated Rating of Strong-Buy.
Recent Insider Trading Activity For NASDAQ:KIN – Kindred Biosciences (NASDAQ:KIN)
NASDAQ:KIN – Kindred Biosciences (NASDAQ:KIN) has insider ownership of 15.96% and institutional ownership of 64.22%.
- On 5/1/2018 Richard Chin, Insider, sold 20,000 with an average share price of $9.05 per share and the total transaction amounting to $181,000.00.
- On 4/2/2018 Richard Chin, Insider, sold 20,000 with an average share price of $8.39 per share and the total transaction amounting to $167,800.00.
- On 3/16/2018 Raymond Townsend, Director, sold 2,670 with an average share price of $9.45 per share and the total transaction amounting to $25,231.50.
- On 3/12/2018 Raymond Townsend, Director, sold 91 with an average share price of $9.45 per share and the total transaction amounting to $859.95.
- On 1/2/2018 Raymond Townsend, Director, sold 6,419 with an average share price of $9.45 per share and the total transaction amounting to $60,659.55.
- On 7/12/2017 Park West Asset Management Llc, Major Shareholder, bought 600,000 with an average share price of $7.50 per share and the total transaction amounting to $4,500,000.00.
- On 7/3/2017 Richard Chin, Insider, sold 13,000 with an average share price of $8.26 per share and the total transaction amounting to $107,380.00.
Recent Trading Activity for NASDAQ:KIN – Kindred Biosciences (NASDAQ:KIN)
Shares of NASDAQ:KIN – Kindred Biosciences closed the previous trading session at 9.85 up +0.15 1.55% with shares trading hands.